Answers are grounded in this paper and cite their sources.
Objective: This study aimed to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) versus the standard of care (SoC) for patients with mild-to-moderate coronavirus disease 2019 (COVID-19) at high risk for progression to severe illness from the perspective of the Italian National Health Service.Methods: A cost-effectiveness model was developed using a closed cohort of 1,000 infected patients. It employeda short-term decision tree (1 year) followed by a lifetime 2-state Markov model (alive and dead). Theshort-term decision tree captured costs and outcomes associated with the primary infection and healthcare utilization; survivors of the short-term decision tree were followed until death to calculate Italian quality-adjustedlife years (QALYs), adjusted in the short-term for survivors to mechanical ventilation. Baseline hospitalization rateand NMV/r effectiveness were sourced from the Istituto Superiore di Sanità (ISS) and the randomized clinical trialEvaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR), respectively. Other inputs weregiven by previous COVID-19 studies and publicly available sources. Sensitivity analyses were conducted for allmodel inputs to test the robustness of the results of the model.Results: NMV/r presented an advantageous cost-effectiveness ratio of 2,237 €/QALY, compared to the SoC, in thelong-term horizon (30 years). Results were most sensitive to baseline risk of hospitalization and NMV/r treatmenteffectiveness parameters. The probabilistic analysis indicated that NMV/r has a 100% probability of being costeffective at a 33,004 € willingness-to-pay threshold.Conclusions: From the Italian National Health Service perspective, NMV/r is cost-effective compared to the standard of care for patients at high risk for severe COVID-19.
No takes yet. Share an insight, caveat, or question.
Moreno et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: